Evaluation of Desmopressin Effect on Primary Haemostasis in Pediatric Patients with Aspirin-Like Defect as Hereditary Thrombocytopathy

Tauer, Josephine T.; Gneuss, A.; Lohse, Judith; Jurgens, Tannis; Knöfler, Ralf

doi:10.1055/s-0031-1275347

Cited by 13 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5,[31][32][33] However, our data appear to be in contrast with 1 study published by Balduini et al 18 reporting an enhancement of collagen-and ADP-induced platelet aggregation. In addition to different experimental conditions (whole blood anticoagulated with sodium heparin vs buffered citrate), the main reason for the discrepant finding may rely on the time course of the effect.…”

Section: Discussioncontrasting

confidence: 99%

The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects

Colucci

Stutz

Rochat

et al. 2014

Blood

View full text Add to dashboard Cite

Key Points• DDAVP is the drug of choice for mild hemophilia A and von Willebrand disease and (by unclear mechanisms) for platelet function disorders.• In vivo DDAVP selectively and markedly enhances the ability to form procoagulant platelets by enhancing intracellular Na 1 and Ca 21 fluxes.is clinically efficacious in patients with mild platelet function disorders but it is not known which mechanisms mediate this effect. Our aim was to evaluate the impact of in vivo DDAVP administration in these patients. We assessed von Willebrand factor (VWF), factor VIII, platelet activation and aggregation, platelet-dependent thrombin generation, and platelet intracellular Na 1 /Ca 21 fluxes, before and 2 and 4 hours after DDAVP (0.3 mg/kg). We found (1) no significant changes for P-selectin expression, PAC-1 binding, d-granule content and secretion, and platelet-aggregation; (2) significant decreases of secretion of a-granules and GPIIb-IIIa activation induced by adenosine 59-diphosphate, convulxin, and thrombin; (3) significant increases of procoagulant platelets induced by convulxin/thrombin and platelet-dependent thrombin generation; and (4) significant increases of intracellular Na 1 /Ca 21 concentrations. We show that in vivo DDAVP selectively and markedly enhances the ability to form procoagulant platelets and increases platelet-dependent thrombin generation by enhancing Na

show abstract

Section: Discussioncontrasting

confidence: 99%

The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects

Colucci

Stutz

Rochat

et al. 2014

Blood

View full text Add to dashboard Cite

show abstract

“…612 The DDAVP-induced improvement of primary haemostasis in patients with aspirin-like defect is mainly due to the marked increase of the VWF. 613 However, the quantitative laboratory measurement of the response to DDAVP in patients with IBDs other than VWD or haemophilia is still uncertain, and the use of DDAVP remains empirical. 570 Recently, it was shown that DDAVP selectively enhances the platelet procoagulant activity which appears to be an additional mechanism to the increase of VWF level.…”

Section: Platelet Defects Recommendationsmentioning

confidence: 99%

Management of severe perioperative bleeding

Kozek‐Langenecker

Ahmed

Afshari

et al. 2017

European Journal of Anaesthesiology

694

316

View full text Add to dashboard Cite

: The management of perioperative bleeding involves multiple assessments and strategies to ensure appropriate patient care. Initially, it is important to identify those patients with an increased risk of perioperative bleeding. Next, strategies should be employed to correct preoperative anaemia and to stabilise macrocirculation and microcirculation to optimise the patient's tolerance to bleeding. Finally, targeted interventions should be used to reduce intraoperative and postoperative bleeding, and so prevent subsequent morbidity and mortality. The objective of these updated guidelines is to provide healthcare professionals with an overview of the most recent evidence to help ensure improved clinical management of patients. For this update, electronic databases were searched without language restrictions from 2011 or 2012 (depending on the search) until 2015. These searches produced 18 334 articles. All articles were assessed and the existing 2013 guidelines were revised to take account of new evidence. This update includes revisions to existing recommendations with respect to the wording, or changes in the grade of recommendation, and also the addition of new recommendations. The final draft guideline was posted on the European Society of Anaesthesiology website for four weeks for review. All comments were collated and the guidelines were amended as appropriate. This publication reflects the output of this work.

show abstract

“…Als selektiver Agonist am Argininvasopressinrezeptor-2 zeigt es einen antidiuretischen, aber keinen vasokonstriktorischen Effekt. Desmopressin kommt als prophylaktische und therapeutische Maßnahme bei vielen angeborenen Thrombozytenfunktionsstörungen infrage (12,13).…”

Section: Desmopressin (Ddavp)unclassified